ALDX - CIK 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | $59.34M | $41.24M | $50.35M | $68.12M | $71.03M |
| Short-term investments | - | $15.96M | $40.68M | $39.71M | $44.62M | $49.30M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $66.27M |
| $77.46M |
| $84.56M |
| $92.73M |
| $116.72M |
| $125.65M |
| Property, plant & equipment | - | - | - | - | $1.36K | $2.72K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $66.48M | $77.80M | $84.96M | $93.20M | $117.32M | $126.04M |
| Accounts payable | $141.36K | $13.42K | $1.46M | $346.15K | $186.92K | $254.43K |
| Total current liabilities | $24.33M | $28.48M | $29.53M | $14.29M | $17.15M | $27.59M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $15.10M | $15.00M | $0.00 |
| Total liabilities | $24.33M | $28.56M | $29.67M | $29.60M | $32.22M | $27.73M |
| Retained earnings | -$487.41M | -$477.50M | -$469.81M | -$460.04M | -$434.30M | -$419.19M |
| Total equity | $42.16M | $49.24M | $55.29M | $63.60M | $85.10M | $98.31M |